Allogene Therapeutics Inc. (ALLO) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Allogene Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Price
$1.30
+5.69% today
Market cap
$425M
Overall quality
38/100
Kronos AI 30-day
+49.8%
8 of 8 simulated paths end higher
Allogene Therapeutics Inc. (ALLO) is a Health Care company in Biotechnology: Biological Products (No Diagnostic Substances), worth $425M. It trades at $1.30, up 5.69% today. Its overall quality score is 38 out of 100, ranked against the whole US market. 6 analysts' average target of $10.25 implies +688.5% from today's price. Kronos AI's 30-day forecast is +49.8% (8 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $10.25 |
| Low – high | $8.00 – $14.00 |
| Analysts | 6 |
| Upside to average | +688.5% |
Kronos AI 30-day forecast
| Expected close | $1.84 (+49.8%) |
| Likely range | +43.7% … +67.7% |
| As of | 2026-10-27 |
8 of 8 simulated paths end higher.
Quality scores
| Profitability | 9 |
| Solvency | 56 |
| Growth | 49 |
| Overall | 38 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Biological Products (No Diagnostic Substances)
For information only, not investment advice. Prices updated: 2026-10-29.